Variant · Structural
KMT2A Translocation
CI-VAR-00004370Explore in graph →CIViC 5066
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 39121437
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Acute Leukemia1 | ||||||||
| KMT2A Translocation | Revumenib | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID12214In the phase I/II trial AUGMENT-101 (NCT04065399), 94 patients (71 adults and 23 children under 18 years) with KMT2A-rearranged acute leukemia received at least one dose of revumenib. Among them, 78 p… (full text at CIViC) PMID 39121437 · Issa et al., 2024 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.